C.M. Bidwell & Associates’s Acorda Therapeutics ACOR Stock Holding History

C.M. Bidwell & Associates’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-34	Closed	-$63K	–	490
2018 Q4	$63K	Buy	+34	New	+$74K	0.07%	229

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

C.M. Bidwell & Associates's ACOR Position: Q1 2019 in Review

C.M. Bidwell & Associates sold out of Acorda Therapeutics (ACOR) in Q1 2019, closing a stake of 34 shares — an estimated $63K sold.

C.M. Bidwell & Associates first reported a position in ACOR in Q4 2018 and held it in 1 quarter. The position peaked at $63K in Q4 2018. 184 funds tracked by Wall St. Rank hold ACOR as of Q1 2019.

C.M. Bidwell & Associates reported no remaining Acorda Therapeutics position as of Q1 2019 after selling out during the quarter.
C.M. Bidwell & Associates sold 34 Acorda Therapeutics shares in Q1 2019, an estimated $63K.
C.M. Bidwell & Associates first reported a position in Acorda Therapeutics in Q4 2018 and held it in 1 quarter.
C.M. Bidwell & Associates's Acorda Therapeutics position peaked at $63K in Q4 2018.
184 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2019.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2019, filed 15 May 2019.